

Calixta.com List of Medicines  
from <https://calixta.com/medicines>

| Medicine                             | Trade Name                          | Category                             | Sub-category 1                              | Sub-category 2       | Year of First FDA ap | Types of Cancer   |
|--------------------------------------|-------------------------------------|--------------------------------------|---|----------------------|----------------------|---|
| Vemurafenib                          | Vizimpro                            | Kinase Inhibitor                     | CRK (Cyclin-Dependent Kinase) Inhibitor     |                      | 2011                 | breast cancer   |
| Abiraterone                          | Zytiga                              | Anti-Androgen                        | CYP17A1 Inhibitor                           |                      | 2011                 | prostate cancer   |
| Caliculinib                          | Cakquence                           | Kinase Inhibitor                     | BTk Inhibitor                               |                      | 2017                 | marble cell carcinoma, chronic lymphocytic leukemia   |
| Actinomycin-D                        | Act-D, Cosmegen, D, Antibiotic      |                                      |   |                      | 1964                 | many sarcomas and some carcinomas   |
| Ado-trastuzumab                      | Kadcyla                             | Antibody-drug conjugate              | HER2 Inhibitor                              |                      | 2019                 | breast cancer   |
| Afinib                               | Gleevec                             | Kinase Inhibitor                     |   |                      | 2013                 | non-small cell lung cancer  |
| Adalimumab                           | Humira                              | Immunomodulator                      |   |                      | 1992                 | metastatic, renal cell carcinoma  |
| Alembic                              | Alemona                             | Kinase Inhibitor                     |   |                      | 2015                 | non-small cell lung cancer  |
| Atemizumab                           | CamPATH                             | Monoclonal Antibody                  |   |                      | 2014                 | B-cell chronic lymphocytic leukemia   |
| Apelresib                            | Piqray                              | PI3K Inhibitor                       |   |                      | 2019                 | breast cancer   |
| Atretonin                            | Parerfin, Toclino                   | Retinoid                             |   |                      | 1999                 | Kapoor's sarcoma  |
| Atratinine                           | Hexalen                             | Akylating agent                      |   |                      | 1990                 | ovarian cancer  |
| Amivantamab-vmj                      | Rybrent                             | Monoclonal Antibody                  |   |                      | 2021                 | non-small cell lung cancer  |
| Astroguelesimab                      | Cytadren                            | Aromatase Inhibitor                  |   |                      | 1990                 | breast cancer, prostate cancer  |
| Azacitidine                          | Accutane                            | Retinoid                             |   |                      | 1995                 | breast cancer   |
| Apalutamide                          | Eriecta                             | Anti-Androgen                        |   |                      | 2019                 | prostate cancer   |
| Arsenic Trioxide                     | Other                               |                                      |   |                      | 2000                 | leukemia  |
| Asciminib                            | Scemblix                            | Kinase Inhibitor                     |   |                      | 2021                 | leukemia  |
| Asapargase, L-asip Elisgar, Kidriase | Enzyme                              |                                      |   |                      | 2011                 | acute lymphocytic leukemia  |
| Atezolizumab                         | Tecentriq                           | Monoclonal Antibody                  | checkpoint inhibitor                        | Anti-PD-1            | 2016                 | small cell lung cancer, urothelial carcinoma, breast cancer, non-small cell lung cancer   |
| Auaptinib                            | Ayvalit                             | Kinase Inhibitor                     |   |                      | 2020                 | gastrointestinal stromal tumor  |
| Avelumab                             | Bavencio                            | Monoclonal Antibody                  | checkpoint inhibitor                        | Anti-PD-1            | 2017                 | metastatic carcinoma, renal cell carcinoma, urothelial carcinoma  |
| Axicabtagene                         | Yesarta                             | CAR T-Cell therapy                   |   |                      | 2017                 | lymphoma  |
| Avitinib                             | Inlyta                              | Kinase Inhibitor                     | VEGF/VEGFR Inhibitor                        |                      | 2012                 | renal cell carcinoma  |
| Azacitidine                          | Vidaza                              | Antimetabolite                       |   |                      | 2004                 | myelodysplastic syndromes, leukemia   |
| Belatramab mab001 Belnep             | Monoclonal Antibody                 |                                      |   |                      | 2020                 | multiple myeloma  |
| Belzutifan                           | Beqmetiq                            | H2AC Inhibitor                       |   |                      | 2014                 | lymphoma  |
| Benadamine                           | Tasanda                             | Akylating Agent                      | Mustard                                     |                      | 2008                 | B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia   |
| Bevacizumab                          | Avastin                             | Monoclonal Antibody                  | Angiogenesis Inhibitor                      | VEGF/VEGFR Inhibitor | 2004                 | colorectal cancer, renal cell carcinoma, cervical cancer, glioblastoma, non-squamous non-small cell lung cancer, ovarian epithelial cancer  |
| Beclomethasone                       | Targetrin                           | Retinoid                             |   |                      | 1999                 | Skin problems caused by cutaneous T cell lymphoma   |
| Bicalutamide                         | Casodex                             | Anti-Androgen                        |   |                      | 1995                 | prostate cancer   |
| Bimotefinib                          | Mektovi                             | Kinase Inhibitor                     |   |                      | 2018                 | melanoma  |
| Bismuthyn                            | Bismuvane                           | Antibiotic                           |   |                      | 1979                 | lymphoma, melanoma, sarcoma, ovarian cancer, testicular cancer  |
| Bisuturumab                          | Bimoty                              | Monoclonal Antibody                  |   |                      | 2014                 | B-cell acute lymphoblastic leukemia   |
| Bortezomib                           | Velcade                             | Proteasome Inhibitor                 |   |                      | 2003                 | multiple myeloma, multiple myeloma  |
| Bosutinib                            | Bosulf                              | Kinase Inhibitor                     | Bcr-Abl Inhibitor                           |                      | 2012                 | chronic myelogenous leukemia  |
| Brentuximab vedotin                  | Adcetris                            | Antibody-drug conjugate              |   |                      | 2011                 | peripheral T-cell lymphoma, cutaneous T-cell lymphoma, Hodgkin's Disease, anaplastic large cell lymphoma  |
| Briqinib                             | Akurinb                             | Kinase Inhibitor                     | ALK Inhibitor                               |                      | 2017                 | non-small cell lung cancer  |
| Brucefinib                           | Mivenc                              | Akylating Agent                      | Amyl sulfonate                              |                      | 1999                 | chronic myelogenous leukemia  |
| Calzastrol                           | Jardiance                           | Mitotic Inhibitor                    | Tasare                                      |                      | 2010                 | prostate cancer   |
| Cabozantinib                         | Cabometyx                           | Kinase Inhibitor                     | VEGF/VEGFR Inhibitor                        |                      | 2012                 | renal cell carcinoma, hepatocellular carcinoma, medullary thyroid cancer  |
| Calaspargase pegyl-4                 | Asparlas                            | Enzyme                               |   |                      | 2018                 | acute lymphoblastic leukemia  |
| Camptothecin                         | Camptosar                           | Topoisomerase Inhibitor              |   |                      | 2012                 | colon cancer, rectal cancer   |
| Capecitabine                         | Xeloda                              | Antimetabolite                       | Prodrug of Fluorouracil                     |                      | 2005                 | breast cancer, colorectal cancer  |
| Capmatinib                           | Tafelra                             | Kinase Inhibitor                     |   |                      | 2020                 | non-small cell lung cancer  |
| Carboplatin                          | Paraplatin                          | Akylating Agent                      | Platinum compound                           |                      | 1989                 | ovarian cancer and other types  |
| Carfilzomib                          | Kyprolis                            | Proteasome Inhibitor                 |   |                      | 2012                 | multiple myeloma  |
| Carmustine                           | BCNU                                | Akylating Agent                      | Nitrosourea                                 |                      | 1996                 | brain tumors, Hodgkin's Disease, multiple myeloma, Non-Hodgkin's lymphoma   |
| Cemiplimab-rwc                       | Libtayo                             | Monoclonal Antibody                  | checkpoint inhibitor                        | Anti-PD-1            | 2018                 | cutaneous squamous cell carcinoma   |
| Ceritinib                            | Zykadia                             | Kinase Inhibitor                     | ALK Inhibitor                               |                      | 2014                 | non-small cell lung cancer  |
| Cetuximab                            | Erbux                               | Monoclonal Antibody                  | EGFR Inhibitor                              |                      | 2009                 | colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer   |
| Cetuximab                            | Cite                                | Antimetabolite                       |   |                      | 2014                 | acute lymphoblastic leukemia  |
| Chloracetyl                          | Leukeran                            | Akylating Agent                      | Mustard                                     |                      | 1967                 | Chronic lymphocytic leukemia, Hodgkin's disease, Non-Hodgkin's lymphoma, ovarian cancer, testicular cancer, and others  |
| Cisplatin                            | Platinol                            | Akylating Agent                      | Platinum compound                           |                      | 1978                 | bladder cancer, testicular cancer, ovarian cancer, esophageal, lung, breast, cervical, stomach and prostate cancers   |
| Cixutumab                            | Lixa and Movectro                   | Antimetabolite                       | Adenosine deaminase Inhibitor               |                      | 1993                 | hairy cell leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma   |
| Cobimetinib                          | Cotelic                             | MEK Inhibitor                        |   |                      | 2015                 | melanoma  |
| Coglitinib                           | Allopa                              | PI3K Inhibitor                       |   |                      | 2017                 | follicular lymphoma   |
| Colesefen                            | Xalxin                              | Kinase Inhibitor                     |   |                      | 2011                 | non-small cell lung cancer  |
| Cyclophosphamide                     | Eribox, Cycloxin, N-Akylating Agent | Mustard                              |   |                      | 1959                 | Refractory, Chronic myelogenous leukemia, Hodgkin's disease, Multiple myeloma, Mycosis fungoides, Neuroblastoma, Non-Hodgkin lymphoma, Acute lymphoblastic leukemia, Acute monocytic leukemia, Acute myeloid leukemia, Breast cancer, Chronic granulocytic leukemia, Chronic lymphocytic leukemia |
| Cytarabine                           | Cytosar-U, Azanbyry Arabinoside     | Antibiotic                           |   |                      | 1969                 | Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Chronic myelogenous leukemia (CM), promyelocytic leukemia   |
| Dabrafenib                           | Tafnar                              | Kinase Inhibitor                     | BRAF Inhibitor                              |                      | 2013                 | anaplastic thyroid cancer, melanoma, non-small cell lung cancer   |
| Dacarbazine                          | DTIC, DTIC-Dome                     | Akylating Agent                      |   |                      | 1975                 | melanoma, Hodgkin's Disease, sarcomas, neuroblastoma, and thyroid cancer  |
| Dacomitinib                          | Vizpro                              | Kinase Inhibitor                     | EGFR Inhibitor                              | HER2 Inhibitor       | 2018                 | non-small cell lung cancer  |
| Daratumumab                          | Darzalex                            | Monoclonal Antibody                  |   |                      | 2015                 | multiple myeloma  |
| Daridorexifen                        | Nubeqa                              | Anti-Androgen                        |   |                      | 2018                 | prostate cancer   |
| Dasatinib                            | Sprycel                             | Kinase Inhibitor                     | Bcr-Abl Inhibitor                           |                      | 2006                 | acute myeloid leukemia, chronic lymphocytic leukemia  |
| Daunorubicin                         | DauNokone, Cenob, Anthracycline     | Antibiotic                           |   |                      | 1979                 | acute lymphoblastic leukemia, acute myelogenous leukemia, acute promyelocytic leukemia  |
| Decitabine                           | Daogen                              | Antimetabolite                       | Cytosine Analog                             |                      | 2006                 | Myelodysplastic syndromes   |
| Degarelix                            | Firmagon                            | Anti-Androgen                        |   |                      | 2008                 | prostate cancer   |
| Denileukin difitox                   | Ortak                               | Antibody-drug conjugate              |   |                      | 1999                 | leukemia and lymphoma   |
| Denitumab                            | Unimab                              | Monoclonal Antibody                  |   |                      | 2015                 | neuroblastoma   |
| Doxistat                             | Taveler                             | Mitotic Inhibitor                    | Isaane                                      |                      | 1996                 | breast, prostate, stomach cancer, non-small cell lung cancer, head and neck cancer  |
| Dostarlimab-gly                      | Jemperli                            | Monoclonal Antibody                  |   |                      | 2021                 | endometrial cancer  |
| Doxorubicin                          | Adriamycin                          | Anthracycline                        | Antibiotic                                  |                      | 1974                 | lymphoblastic and myeloid leukemia, breast cancer, stomach cancer, Hodgkin's lymphoma, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, small cell lung cancer, soft tissue and bone sarcomas, thyroid cancer, bladder cancer, Wilms tumor  |
| Durvalumab                           | Imfinzi                             | Monoclonal Antibody                  | checkpoint inhibitor                        | Anti-PD-1            | 2017                 | non-small cell lung cancer, urothelial carcinoma  |
| Duvulast                             | Copiktra                            | PI3K Inhibitor                       |   |                      | 2018                 | follicular lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma   |
| Eltisumab                            | Emplicit                            | Monoclonal Antibody                  |   |                      | 2015                 | multiple myeloma  |
| Enzalutamide                         | Xtandi                              | Anti-Androgen                        |   |                      | 2018                 | prostate cancer   |
| Encorafenib                          | Braftovi                            | Kinase Inhibitor                     | BRAF Inhibitor                              |                      | 2018                 | melanoma  |
| Enfortumab vedotin-e Padrov          | Antibody-drug conjugate             |                                      |   |                      | 2019                 | urothelial cancer   |
| Ertectinib                           | Rozlytrek                           | Kinase Inhibitor                     |   |                      | 2019                 | non-small cell lung cancer  |
| Ergazole                             | Xtandi                              | Anti-androgen                        |   |                      | 2012                 | prostate cancer   |
| Eprazinib                            | Elence                              | Anthracycline                        | Antibiotic                                  |                      | 1999                 | breast cancer   |
| Eristatib                            | Baletra                             | Kinase Inhibitor                     | FGFR Inhibitor                              |                      | 2019                 | urothelial carcinoma and bladder cancer   |
| Erlotinib                            | Havlen                              | Mitotic Inhibitor                    |   |                      | 2010                 | breast cancer   |
| Erlotinib                            | Tarceva                             | Kinase Inhibitor                     | EGFR Inhibitor                              |                      | 2004                 | pancreatic cancer, non-small lung cancer  |
| Estramustine                         | Envyt, Estract                      | Hormone Suppressant                  | Mustard                                     |                      | 1981                 | prostate cancer   |
| Etoposide                            | Eposin, Vepesid                     | Topoisomerase Inhibitor              | plant alkaloid                              |                      | 1983                 | small cell lung cancer, testicular cancer   |
| Everolimus                           | Afinic, Zorast                      | mTOR Inhibitor                       |   |                      | 2010                 | kidney, breast, pancreatic, gastrointestinal, lung cancer, sarcomas, lymphomas  |
| Euxemoline                           | Amisul                              | Antimetabolite                       |   |                      | 1999                 | breast cancer   |
| Fan-trastuzumab emtansin             | Antibody-drug conjugate             |                                      |   |                      | 2019                 | breast cancer   |
| Fluorouracil (5-FU)                  | Aduci                               | Antimetabolite                       |   |                      | 1962                 | bladder, anal, breast, gastrointestinal, thymic, cervical, head and neck, and colorectal cancer   |
| Flouridone                           | FUDR                                | Antimetabolite                       | pyrimidine analog                           |                      | 1970                 | stomach, colon, kidney cancer   |
| Flutamide                            | Flutara                             | Antimetabolite                       | purine analog                               |                      | 1991                 | lymphocytic leukemia, non-Hodgkin's lymphoma  |
| Flutamide                            | Eulexin                             | Anti-androgen                        |   |                      | 1989                 | prostate cancer   |
| Fulvestrant                          | Faslodex                            | Anti-androgen                        |   |                      | 2002                 | breast cancer   |
| Gallein                              | Inasa                               | Kinase Inhibitor                     | EGFR Inhibitor                              |                      | 2003                 | non-small cell lung cancer  |
| Gemcitabine                          | Gemzar                              | Antimetabolite                       | Nucleoside analog                           |                      | 1996                 | sarcoma, pancreatic cancer, ovarian cancer, breast cancer, non-small cell lung cancer   |
| Gemtuzumab ozogamir Mylotarg         | Antibody-drug conjugate             |                                      |   |                      | 2017                 | acute myeloid leukemia  |
| Gilteritinib                         | Xospata                             | Kinase Inhibitor                     |   |                      | 2018                 | acute myeloid leukemia  |
| Glasdegib                            | Daurismo                            | Hedgehog signaling pathway inhibitor |   |                      | 2018                 | acute myeloid leukemia  |
| Goserelin                            | Zoladex                             | Hormone suppressant                  |   |                      | 1989                 | prostate cancer, breast cancer  |
| Hidralin                             | Varitas, Supprelin                  | Hormone suppressant                  |   |                      | 2004                 | prostate cancer   |
| Hydroxyurea                          | Hydrea, Droxia, Mylo                | Antimetabolite                       | Inhibitor of the enzyme ribonucleotide red. |                      | 1967                 | chronic myelogenous leukemia, squamous cell carcinoma of the head and neck, melanoma, ovarian cancer  |
| Ibrutinib                            | Zevalin                             | Antibody-drug conjugate              |   |                      | 2002                 | B-cell non-Hodgkin's lymphoma   |
| Ibrutinib                            | Imbruvica                           | Kinase Inhibitor                     | BTk Inhibitor                               |                      | 2013                 | Waldenström macroglobulinemia, marginal zone lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma   |
| Idarubicin                           | Idamycin                            | Anthracycline                        | Antibiotic                                  |                      | 1980                 | lymphoblastic and myelogenous leukemia, myelodysplastic syndromes   |
| Idelalisib                           | Zydelig                             | PI3K Inhibitor                       |   |                      | 2014                 | chronic lymphocytic leukemia, non-Hodgkin's lymphoma  |
| Ioflupridine                         | Milozona, Iofex                     | Akylating Agent                      |   |                      | 1988                 | sarcoma, lymphoma, leukemia, testicular, bladder, lung cancer   |
| Imatinib                             | Gleevec                             | Kinase Inhibitor                     | Bcr-Abl Inhibitor                           |                      | 2001                 | chronic myelocytic leukemia, hyperosplenitic syndrome, chronic myelogenous leukemia, dermatofibrosarcoma protuberans, gastrointestinal stromal tumor, myelodysplastic/myeloproliferative neoplasms, systemic mastocytosis   |
| Infliximab                           | Tasactiq                            | Kinase Inhibitor                     |   |                      | 2021                 | cholangiocarcinoma  |
| Inotuzumab ogansin                   | Bespoma                             | Antibody-drug conjugate              |   |                      | 2017                 | B-cell non-Hodgkin lymphoma   |
| Ipiimumab                            | Yervey                              | Monoclonal Antibody                  | checkpoint inhibitor                        | Anti-CTLA-4          | 2011                 | melanoma, colorectal cancer, hepatocellular carcinoma, mesothelioma, non-small cell lung cancer, renal cell carcinoma   |
| Irinotecan                           | Camptosar                           | Topoisomerase Inhibitor              |   |                      | 1996                 | colorectal cancer   |
| Interferon                           | Interon A, Roferon A                | Immunomodulator                      |   |                      | 1986                 | Kapoor's sarcoma, hairy cell leukemia, melanoma, follicular lymphoma  |
| Izalupimab                           | Sarisa                              | Monoclonal Antibody                  |   |                      | 2020                 | multiple myeloma  |
| Ipilimumab                           | Reccazzane                          | Retinoid                             |   |                      | 1982                 | neuroblastoma in children, cutaneous T-Cell lymphoma, squamous cell skin cancers  |
| Ivacaftor                            | Tasvo                               | ICM1 Inhibitor                       |   |                      | 2018                 | acute myeloid leukemia  |
| Ixabepone                            | Azapethione B                       | Mitotic Inhibitor                    |   |                      | 2007                 | breast cancer   |
| Izaximib                             | Ninlaro                             | Proteasome Inhibitor                 |   |                      | 2015                 | multiple myeloma  |
| Lapatinib                            | Tykerb                              | Kinase Inhibitor                     | EGFR Inhibitor                              | HER2 Inhibitor       | 2007                 | breast cancer   |
| Larotrectinib                        | Vitrakvi                            | Kinase Inhibitor                     | Tropomyosin Receptor                        |                      | 2018                 | solid tumors  |
| Levamisole                           | Revlimid                            | Immunomodulatory                     | Angiogenesis Inhibitor                      |                      | 2005                 | myelodysplastic syndromes, myeloma, mantle cell lymphoma  |
| Lenvatinib                           | Larvima                             | Kinase Inhibitor                     | VEGF/VEGFR Inhibitor                        |                      | 2015                 | thyroid cancer, renal cell carcinoma, liver cancer, endometrial cancer  |
| Letrozole                            | Femara                              | Aromatase Inhibitor                  |   |                      | 1997                 | breast cancer   |
| Leuprolide                           | Vuilar, Eligard                     | Hormone Suppressant                  |   |                      | 1985                 | prostate, breast, ovarian, endometrial cancer   |
| Lomustine                            | Gleostine                           | Akylating Agent                      | Nitrosourea                                 |                      | 1976                 | brain tumors, Hodgkin's Disease   |
| Lomustine                            | Zyronis                             | Antibody-drug conjugate              |   |                      | 2021                 | lymphoma  |
| Lorazepam                            | Loriprin                            | Kinase Inhibitor                     |   |                      | 2018                 | non-small cell lung cancer  |
| Lurbinectedin                        | Zeposia                             | Akylating Agent                      |   |                      | 2020                 | small cell lung cancer  |
| Luteifum Lu 177                      | Lu177                               | Antibody-drug conjugate              |   |                      | 2018                 | gastroenteropancreatic neuroendocrine tumors  |
| Luteifum Lu 177                      | Aviv                                | Antibody-drug conjugate              |   |                      | 2022                 | prostate cancer   |

